SlideShare a Scribd company logo
By:- 
Ms. Shalini joshi 
m.sc.nsg ist year 
s.c.o.n. dehradun
 Definition of genetic testing 
 Purpose of genetic testing 
Types of genetic testing 
 Basis of genetic testing 
 Prenatal diagnosis and screening 
Common diagnostic test 
Techniques for pathological examination 
 Ethical legal and psychosocial issue in 
genetic testing
 Finding genetic disease in unborn child 
 Finding out if people carry genes for a disease and 
might pass it on to their children. 
 Screening embryos for disease. 
 Testing for genetic disease in adult before they cause 
symptoms. 
 Making a diagnosis in a person who has disease 
symptoms 
 Figuring out the type or dose of a medicine that is 
best for a certain person.
 Genetic testing is defined as “examining a sample of 
blood or other body fluids or tissue for bio-chemical 
chromosomal, or genetic markers that indicate the 
presence or absence of genetic disease.
 A genetic testing is analyzing a DNA to look for 
genetic alteration that may indicate an increased risk 
for developing a specific disease or disorder. 
Or 
 It is also defined as type of medical test, identifies 
changes in chromosomes, genes or proteins.
 Carrier screening which involves identifying unaffected 
individuals who carry one copy for the disease to be 
expressed. 
 Pre implantation genetic diagnosis. 
 Pre natal diagnostic testing. 
 New born screening 
 Pre symptomatic testing for estimating the risk of adult 
onset cancer and alziemer’s disease
 Conformational diagnosis of a symptomatic 
individual. 
 Forensic or identity testing. 
 Pre symptomatic testing for predicting adult onset 
disorders such as Huntington’s chorea. 
 It allows the genetic disorder of vulnerabilities to 
inherited diseases. 
 It can be used to determine a child potentiality or 
person ancestry.
Genetictesting 140305094745-phpapp01
 Quantitative genetic research has built a strong case for 
the importance of genetic factor in many complex 
behavioural disorder and dimensions in the domains of 
psychopathology, personality and cognitive abilities. 
 The genetic basis of behavioural disorder has largely 
relied on a reductionist one gene one disorder (ONOD) 
approach in which a single gene is necessary and 
sufficient to develop a disorder. 
 In contrast a quantitative trait loci approach involves the 
search for multiple genes.
 Managing the remaining weeks of the pregnancy 
 Determining the outcome of the pregnancy 
 Planning for possible complications with the birth 
process 
 Planning for problems that may occur in the newborn 
infant 
 Deciding whether to continue the pregnancy 
 Finding conditions that may affect future pregnancies.
Genetictesting 140305094745-phpapp01
 This is a non-invasive procedure that is harmless to both 
the fetus and the mother. 
 The developing embryo can first be visualized at about 6 
weeks gestation. 
 Recognition of the major internal organs and extremities 
to determine if any abnormality can best be accomplished 
between 16 to 20 weeks gestation.
 the size and position of the fetus, 
 the size and position of the placenta, 
 the amount of amniotic fluid, 
 the appearance of fetal anatomy,
 Abnormalities may not be detected until later in 
pregnancy, or may not be detected at all. 
 A good example of this is Down syndrome (trisomy 21) 
where the morphologic abnormalities are often not 
marked,
 This is an invasive procedure . 
 Amniocenteses are performed between 14 and 20 
weeks gestation. 
 An ultrasound examination always precedes 
amniocentesis 
 In the third trimester of pregnancy, the amniotic fluid can 
be analyzed for determination of fetal lung maturity 
 amniotic fluid can be analyzed for lecithin:sphingomyelin 
(LS) ratio, and/or for phosphatidyl glycerol (PG).
Genetictesting 140305094745-phpapp01
 fetal loss (0.5%) 
 maternal Rh sensitization. 
 If oligohydramnios is present, then amniotic fluid 
cannot be obtained.
 CVS can be safely performed between 9.5 and 12.5 weeks 
gestation. 
 In this procedure, a catheter is passed via the vagina 
through the cervix and into the uterus to the developing 
placenta under ultrasound guidance 
 The introduction of the catheter allows sampling of cells 
from the placental chorionic villi. 
 These cells can then be analyzed by variety of techniques. 
The most common test employed on cells obtained by CVS 
is chromosome analysis to determine the karyotype of the 
fetus.
Genetictesting 140305094745-phpapp01
 This is a new technique that makes use of the phenomenon 
of fetal blood cells gaining access to maternal circulation 
through the placental villi. 
 The fetal cells can be sorted out and analyzed by a variety of 
techniques to look for particular DNA sequences 
 Fluorescence in-situ hybridization (FISH) is one technique 
that can be applied to identify particular chromosomes of the 
fetal cells recovered from maternal blood and diagnose 
aneuploid condition such as the trisomies and monosomy X.
 It is difficult to get many fetal blood cells. 
 There may not be enough to reliably determine 
anomalies of the fetal karyotype or assay for other 
abnormalities.
 The developing fetus has two major blood proteins-albumin 
and alpha-fetoprotein (AFP). 
 The MSAFP test can be utilized to determine the levels of 
AFP from the fetus 
 Ordinarily, only a small amount of AFP gains access to the 
amniotic fluid and crosses the placenta to mother's blood.
 When there is a neural tube defect in the fetus, 
 Then there is a means for escape of more AFP into the 
amniotic fluid. 
 The AFP from the fetus will end up in maternal blood in 
higher amounts. 
 Neural tube defects include anencephaly and spina bifida .
 This test is most commonly used as a test for pregnancy. 
 The beta-HCG can also be quantified in serum from 
maternal blood, and this can be useful early in pregnancy 
when threatened abortion or ectopic pregnancy 
suspected 
 because the amount of beta-HCG will be lower than 
expected.
 An elevated beta-HCG coupled with a decreased MSAFP 
suggests Down syndrome. 
 Very high levels of HCG suggest trophoblastic disease 
(molar pregnancy). 
 The absence of a fetus on ultrasonography along with an 
elevated HCG suggests a hydatidiform mole 
 The HCG level can be used to follow up treatment for 
molar pregnancy to make sure that no trophoblastic 
disease, such as a choriocarcinoma, persists.
The amount of estriol in maternal serum is 
dependent upon a viable fetus, a properly 
functioning placenta, and maternal well-being. 
substrate for estriol begins as 
dehydroepiandrosterone (DHEA) made by the fetal 
adrenal glands 
This is further metabolized in the placenta to 
estriol.
The estriol crosses to the maternal circulation and is 
excreted by the maternal kidney in urine or by the 
maternal liver in the bile 
 The measurement of serial estriol levels in the third 
trimester will give an indication of general well-being of 
the fetus 
 If the estriol level drops, then the fetus is threatened 
and delivery may be necessary emergently 
 Estriol tends to be lower when Down syndrome is 
present and when there is adrenal hypoplasia with 
anencephaly.
 Inhibin is secreted by the placenta and the corpus luteum. 
 Inhibin –A is associated with an increased risk of trisomy 
21, 
 A high inhibin –A may be associated with a risk for preterm 
delivery.
Low levels of PAPP-A as measured in maternal 
serum during the first trimester may be associated 
with fetal chromosomal anomalies including 
trisomies 13, 18, and 21 
Low PAPP-A levels in the first trimester may 
predict an adverse pregnancy outcome, including a 
small for gestational age (SGA) baby or stillbirth. 
A high PAPP-A level may predict a large for 
gestational age (LGA) baby.
 Combining the maternal serum assays may aid in 
increasing the sensitivity and specificity of detection for 
fetal abnormalities. 
 The classic test is the triple screen for alpha-fetoprotein 
(MSAFP), beta-HCG, and estriol (uE3). The "quadruple 
screen" adds inhibin-A.
Genetictesting 140305094745-phpapp01
 It is useful in detecting gross fetal parts. 
 The pattern of gross abnormalities can often suggest a 
possible chromosomal abnormality or a syndrome. 
 Consultations are obtained with clinical geneticists to 
review the findings 
 Examination of the placenta is very important, because the 
reason for the fetal loss may be a placental problem
 Microscopic examination of the placenta is 
important 
Microscopy can aid in determination of 
gestational age (lung, kidney maturity), 
presence of infection, presence of neoplasia, 
or presence of "dysplasia" (abnormal 
organogenesis).
 Radiographic views are essential for analysis of 
the fetal skeleton. 
 Radiographs are useful for comparison with 
prenatal ultrasound, and help define anomalies 
when autopsy consent is limited 
 To determine sites to be examined microscopically.
 Skeletal anomalies (dwarfism, dysplasia, etc.) 
 Neural tube defects (anencephaly, spina bifida, etc.) 
 Osteogenesis imperfecta 
 Soft tissue changes (hydrops, hygroma, etc.) 
 Teratomas or other neoplasms 
 Growth retardation 
 Orientation and audit of fetal parts 
 Assessment of catheter or therapeutic device placement
 Culture can aid in diagnosis or confirmation of congenital 
infections:- 
 T - toxoplasmosis 
 O - other, such as Listeria monocytogenes, group 
B streptococcus, syphilis 
 R - rubella 
 C - cytomegalovirus 
 H - herpes simplex or human immunodeficiency virus 
(HIV)
 Tissues must be obtained as fresh as possible for culture and 
without contamination. 
 A useful procedure is to wash the tissue samples in sterile 
saline prior to placing them into cell culture media. 
 Tissues with the best culture for growth are those with the least 
maceration: placenta, lung, and diaphragm. 
 Obtaining tissue from more than one site can increase the yield 
by avoiding contamination or by detection of mosaicism.
Genetictesting 140305094745-phpapp01
 Patient need to sufficiently informed about the implication of 
genetic screening before they can provide informed 
consent. 
 The public view genetic with a sense of inevitability. 
However, a genetic condition alone may modify risks from 
environmental or life style factor. 
 The voluntary nature of the 
screening process must be 
emphasized.
 To reduce potential psychological distress, counseling 
should be available to provide information about genetic 
risk and explain choices regarding genetic testing and 
further management. 
 Support is needed for individuals who need to consider 
issue such as stigma disclosure to family members and 
confidentiality.
 Couple known to carry a recessive or dominance single 
gene defect or sex linked condition need counseling about 
their reproductive option. This may include prenatal 
diagnosis and possible pregnancy termination in the case 
of an affected fetus and pre-implantation genetic 
diagnosis.
 The public’s understanding of genetic may 
be limited and can lead to sigma. 
 Misunderstanding of the genetic risk of developing disease 
can increase stigmatization. This may be around life 
expectancy, lifestyle choices, or decision about having 
children. 
 Identification of a genetic condition before birth raises issue 
of whether the parents wish to terminate the pregnancy. 
Some commentators have argues that the ability to only 
select perfect babies is a form of eugenesis.
 Confidentiality 
 Like other medical information, result from genetic testing 
are considered confidential, under normal practice, the 
doctor patient relationship protect against disclosure of 
genetic information. 
 However there is less clarity where 
relative wish to know the result of a 
family member’s genetic test, as it may have 
direct relevance for them.
 Another particular dilemma is the case of a pregnant 
woman wanting to know the result of a test taken by the 
baby’s father. 
 The storage of genetic screening data and registries of 
patients creates particular concern, given that the results 
may impact 
negatively on family 
members.
 Doctors face a dilemma when reporting the results of 
genetic screening. Standard medical practice is based on 
the principles that doctor’s should focus on their patient and 
that medical information should remain confidential. 
 It is unclear if doctors are ethically permitted to inform 
relatives in cases when the result of genetic test indicates 
real risk to their health.
 Doctors may also be faced with a decision about whether 
to persuade patient about the need to disclose their test 
result to relatives. 
 Although most professional bodies that disclosure should 
not be against the right of relatives have won priorities.
 The primary concerns among the public is the use of 
genetic information to delay access to health insurance or 
medical treatment. 
 Conversely health insurance claim right to access such 
data where it exist to avoid the moral hazards of patient 
with known condition taking out an insurance policy without 
disclosing this information.
Genetictesting 140305094745-phpapp01
Genetictesting 140305094745-phpapp01
 Dutta D. C. “ textbook of obstetrics” 6th edition, new central book agency (p) 
limited, 2009. 
 Gangane S. D. “human genetics” 3rd edition, Elsevier publishers, 2010. 
 Mandal Sanjay “ fundamentals of human genetics” 2nd edition, New Central 
B 
Book agency, Page no. 209-212. 
 Perry, Lsowdermilk, “Maternity and women’s health care” 8th edition, mosby 
an affiliated 
by Elsevier page no. 67-69. 
 Sharma, Kumar Suresh, “human genetics in nursing, 2nd edition, Jaypee 
Publishers, 2011 
 Internet-www. 
wikepedia.com 
www.sparknotes.com 
www.slideshare.com 
www.pubmed.com 
www.nsgc.org 
www.geneticalliance.org 
 Dictionary – 
Oxford essential dictionary. For learners of English, oxford university press.

More Related Content

PPTX
METHODS OF HEALTH EDUCATION (1).pptx
PPTX
Administration of im injections
PDF
FINAL RURAL VISIT REPORT 2024 .pdf for third year GNM students
PPTX
Review of height & weight techniques
PPTX
Observation skills
PPTX
Special laws and ordinances of child.pptx
PPTX
Current trends in pediatric nursing
METHODS OF HEALTH EDUCATION (1).pptx
Administration of im injections
FINAL RURAL VISIT REPORT 2024 .pdf for third year GNM students
Review of height & weight techniques
Observation skills
Special laws and ordinances of child.pptx
Current trends in pediatric nursing

What's hot (20)

PPTX
0 play activities of normal and hospitalized child of
PPTX
PDF
INDEPENDENT PRACTICE ISSUES.pdf
PPTX
Objective Structured Clinical Examination (OSCE)
PPTX
Drugs Dispensing and Injections at Health Centre.pptx
PPTX
Record and reports for nurses
PPTX
Forensic Medicine and Forensic team , Forensic Experts
PPTX
Child welfare
PPTX
Counselling in nusing
PPTX
Distance education in nursing
PPTX
planning for health education.pptx
PPTX
Clinical evaluation methods by Tanoj Patidar MSc Nursing (MSN)
PPTX
National health policy for children
PPT
Importance of Play
PPTX
Ors-preparation
PDF
Bandage
PPT
High risk neonate
PPTX
PPTX
Pediatric Research study
0 play activities of normal and hospitalized child of
INDEPENDENT PRACTICE ISSUES.pdf
Objective Structured Clinical Examination (OSCE)
Drugs Dispensing and Injections at Health Centre.pptx
Record and reports for nurses
Forensic Medicine and Forensic team , Forensic Experts
Child welfare
Counselling in nusing
Distance education in nursing
planning for health education.pptx
Clinical evaluation methods by Tanoj Patidar MSc Nursing (MSN)
National health policy for children
Importance of Play
Ors-preparation
Bandage
High risk neonate
Pediatric Research study
Ad

Viewers also liked (20)

PDF
L4 key slides ferlin
PPT
9112217224571
PPT
Mjd presentation1 (2)
PDF
Applicationofngstechnologiestopreimplantationgeneticdiagnosis 140406120933-ph...
PPT
自主原則2009 11-17 蔡明哲教授-
PPTX
Mitalipov
PPT
Dr. irene souter pgd stickler foundation (2)
PDF
L5 key slides montag
PDF
Other potential definitions of success in art itt, et,
PDF
Methods fo
PDF
Endometrial infusion of human chorionic gonadotropin
PPT
Presentation instabul +videos 1 6-2010
PPT
Embryo 090423111342-phpapp02
PDF
Drkenmaclean 130523003241-phpapp01
PPT
Mjd presentation1 (1)
PDF
L6 key slides meseguer
PDF
Genet mo
PPT
New developments in reproductive medicine
PPTX
Nextgenerationsequencing 131218163555-phpapp02
PDF
Post pn-445 (2)
L4 key slides ferlin
9112217224571
Mjd presentation1 (2)
Applicationofngstechnologiestopreimplantationgeneticdiagnosis 140406120933-ph...
自主原則2009 11-17 蔡明哲教授-
Mitalipov
Dr. irene souter pgd stickler foundation (2)
L5 key slides montag
Other potential definitions of success in art itt, et,
Methods fo
Endometrial infusion of human chorionic gonadotropin
Presentation instabul +videos 1 6-2010
Embryo 090423111342-phpapp02
Drkenmaclean 130523003241-phpapp01
Mjd presentation1 (1)
L6 key slides meseguer
Genet mo
New developments in reproductive medicine
Nextgenerationsequencing 131218163555-phpapp02
Post pn-445 (2)
Ad

Similar to Genetictesting 140305094745-phpapp01 (20)

PPTX
Genetic testing
PPTX
UNIT 3 GENETICS.pptx
PPTX
pregnancy &prenatal diagnosisi
PPTX
PRENATAL_DIAGNOSIS[1].pptx
PPTX
genetic tests.pptx
PPT
Prenatal diagnosis
PDF
DIAGNOSTICS.pdf GENETIC EVALUATION AND TREATMENT
PPTX
Genetic counselling 7 march13-Dr.Gourav
PPTX
screening for down syndrome
PPTX
Gene screen technology
PPTX
prenatal diagnosis.ppt..pptx
PPTX
PharmaNiPTGeneticalDemographics MTY.pptx
PPTX
GENETIC MUTATION.pptx (M.Sc Nursing ) I y
PPT
Prenatal cytogenetic
PDF
Reproductive Genetics: Introduction to Genetic Testing Options
PPTX
Sridhar prenatal diagnosis
PPTX
Prenatal and preimplantation diagnosis 22.04.2021
PPTX
Fetal therapy
PPTX
Seminar prenatal genetic screening
PPTX
Genetic screening..dr.padmesh
Genetic testing
UNIT 3 GENETICS.pptx
pregnancy &prenatal diagnosisi
PRENATAL_DIAGNOSIS[1].pptx
genetic tests.pptx
Prenatal diagnosis
DIAGNOSTICS.pdf GENETIC EVALUATION AND TREATMENT
Genetic counselling 7 march13-Dr.Gourav
screening for down syndrome
Gene screen technology
prenatal diagnosis.ppt..pptx
PharmaNiPTGeneticalDemographics MTY.pptx
GENETIC MUTATION.pptx (M.Sc Nursing ) I y
Prenatal cytogenetic
Reproductive Genetics: Introduction to Genetic Testing Options
Sridhar prenatal diagnosis
Prenatal and preimplantation diagnosis 22.04.2021
Fetal therapy
Seminar prenatal genetic screening
Genetic screening..dr.padmesh

More from t7260678 (20)

PPT
Newdevelopment
PPT
Embryology (mo)
PPT
04 implantation
PPT
Munnearraycghupdate201005 12736039844094-phpapp02 (1)
PPT
Human embryonic development
PPT
Recurent art failure_in_evidence_based_medicine_embryologist_perspective
PPT
2a embryonic development
PDF
Implantation of embryo 3
PPT
Munneasrm2009abstracto6 12564080005062-phpapp03
PPTX
Daganasrm2009abstracto268 12564089438001-phpapp02
PPT
Munneoverviewpgdchina200911withsound 12588814598727-phpapp02
PPT
Embryotransferincattle
PPT
Power point
PPT
Embryo transfer in_cattle
PPT
Embryo transfer
PPT
Power point (1)
PPT
Embryo 090423111342-phpapp02 (1)
PPT
複製 Embryo-090423111342-phpapp02 (1)
PPT
Munneoverviewpgdchina200911withsound 12588814598727-phpapp02 (1)
PPT
Embryo transfer in_cattle (1)
Newdevelopment
Embryology (mo)
04 implantation
Munnearraycghupdate201005 12736039844094-phpapp02 (1)
Human embryonic development
Recurent art failure_in_evidence_based_medicine_embryologist_perspective
2a embryonic development
Implantation of embryo 3
Munneasrm2009abstracto6 12564080005062-phpapp03
Daganasrm2009abstracto268 12564089438001-phpapp02
Munneoverviewpgdchina200911withsound 12588814598727-phpapp02
Embryotransferincattle
Power point
Embryo transfer in_cattle
Embryo transfer
Power point (1)
Embryo 090423111342-phpapp02 (1)
複製 Embryo-090423111342-phpapp02 (1)
Munneoverviewpgdchina200911withsound 12588814598727-phpapp02 (1)
Embryo transfer in_cattle (1)

Genetictesting 140305094745-phpapp01

  • 1. By:- Ms. Shalini joshi m.sc.nsg ist year s.c.o.n. dehradun
  • 2.  Definition of genetic testing  Purpose of genetic testing Types of genetic testing  Basis of genetic testing  Prenatal diagnosis and screening Common diagnostic test Techniques for pathological examination  Ethical legal and psychosocial issue in genetic testing
  • 3.  Finding genetic disease in unborn child  Finding out if people carry genes for a disease and might pass it on to their children.  Screening embryos for disease.  Testing for genetic disease in adult before they cause symptoms.  Making a diagnosis in a person who has disease symptoms  Figuring out the type or dose of a medicine that is best for a certain person.
  • 4.  Genetic testing is defined as “examining a sample of blood or other body fluids or tissue for bio-chemical chromosomal, or genetic markers that indicate the presence or absence of genetic disease.
  • 5.  A genetic testing is analyzing a DNA to look for genetic alteration that may indicate an increased risk for developing a specific disease or disorder. Or  It is also defined as type of medical test, identifies changes in chromosomes, genes or proteins.
  • 6.  Carrier screening which involves identifying unaffected individuals who carry one copy for the disease to be expressed.  Pre implantation genetic diagnosis.  Pre natal diagnostic testing.  New born screening  Pre symptomatic testing for estimating the risk of adult onset cancer and alziemer’s disease
  • 7.  Conformational diagnosis of a symptomatic individual.  Forensic or identity testing.  Pre symptomatic testing for predicting adult onset disorders such as Huntington’s chorea.  It allows the genetic disorder of vulnerabilities to inherited diseases.  It can be used to determine a child potentiality or person ancestry.
  • 9.  Quantitative genetic research has built a strong case for the importance of genetic factor in many complex behavioural disorder and dimensions in the domains of psychopathology, personality and cognitive abilities.  The genetic basis of behavioural disorder has largely relied on a reductionist one gene one disorder (ONOD) approach in which a single gene is necessary and sufficient to develop a disorder.  In contrast a quantitative trait loci approach involves the search for multiple genes.
  • 10.  Managing the remaining weeks of the pregnancy  Determining the outcome of the pregnancy  Planning for possible complications with the birth process  Planning for problems that may occur in the newborn infant  Deciding whether to continue the pregnancy  Finding conditions that may affect future pregnancies.
  • 12.  This is a non-invasive procedure that is harmless to both the fetus and the mother.  The developing embryo can first be visualized at about 6 weeks gestation.  Recognition of the major internal organs and extremities to determine if any abnormality can best be accomplished between 16 to 20 weeks gestation.
  • 13.  the size and position of the fetus,  the size and position of the placenta,  the amount of amniotic fluid,  the appearance of fetal anatomy,
  • 14.  Abnormalities may not be detected until later in pregnancy, or may not be detected at all.  A good example of this is Down syndrome (trisomy 21) where the morphologic abnormalities are often not marked,
  • 15.  This is an invasive procedure .  Amniocenteses are performed between 14 and 20 weeks gestation.  An ultrasound examination always precedes amniocentesis  In the third trimester of pregnancy, the amniotic fluid can be analyzed for determination of fetal lung maturity  amniotic fluid can be analyzed for lecithin:sphingomyelin (LS) ratio, and/or for phosphatidyl glycerol (PG).
  • 17.  fetal loss (0.5%)  maternal Rh sensitization.  If oligohydramnios is present, then amniotic fluid cannot be obtained.
  • 18.  CVS can be safely performed between 9.5 and 12.5 weeks gestation.  In this procedure, a catheter is passed via the vagina through the cervix and into the uterus to the developing placenta under ultrasound guidance  The introduction of the catheter allows sampling of cells from the placental chorionic villi.  These cells can then be analyzed by variety of techniques. The most common test employed on cells obtained by CVS is chromosome analysis to determine the karyotype of the fetus.
  • 20.  This is a new technique that makes use of the phenomenon of fetal blood cells gaining access to maternal circulation through the placental villi.  The fetal cells can be sorted out and analyzed by a variety of techniques to look for particular DNA sequences  Fluorescence in-situ hybridization (FISH) is one technique that can be applied to identify particular chromosomes of the fetal cells recovered from maternal blood and diagnose aneuploid condition such as the trisomies and monosomy X.
  • 21.  It is difficult to get many fetal blood cells.  There may not be enough to reliably determine anomalies of the fetal karyotype or assay for other abnormalities.
  • 22.  The developing fetus has two major blood proteins-albumin and alpha-fetoprotein (AFP).  The MSAFP test can be utilized to determine the levels of AFP from the fetus  Ordinarily, only a small amount of AFP gains access to the amniotic fluid and crosses the placenta to mother's blood.
  • 23.  When there is a neural tube defect in the fetus,  Then there is a means for escape of more AFP into the amniotic fluid.  The AFP from the fetus will end up in maternal blood in higher amounts.  Neural tube defects include anencephaly and spina bifida .
  • 24.  This test is most commonly used as a test for pregnancy.  The beta-HCG can also be quantified in serum from maternal blood, and this can be useful early in pregnancy when threatened abortion or ectopic pregnancy suspected  because the amount of beta-HCG will be lower than expected.
  • 25.  An elevated beta-HCG coupled with a decreased MSAFP suggests Down syndrome.  Very high levels of HCG suggest trophoblastic disease (molar pregnancy).  The absence of a fetus on ultrasonography along with an elevated HCG suggests a hydatidiform mole  The HCG level can be used to follow up treatment for molar pregnancy to make sure that no trophoblastic disease, such as a choriocarcinoma, persists.
  • 26. The amount of estriol in maternal serum is dependent upon a viable fetus, a properly functioning placenta, and maternal well-being. substrate for estriol begins as dehydroepiandrosterone (DHEA) made by the fetal adrenal glands This is further metabolized in the placenta to estriol.
  • 27. The estriol crosses to the maternal circulation and is excreted by the maternal kidney in urine or by the maternal liver in the bile  The measurement of serial estriol levels in the third trimester will give an indication of general well-being of the fetus  If the estriol level drops, then the fetus is threatened and delivery may be necessary emergently  Estriol tends to be lower when Down syndrome is present and when there is adrenal hypoplasia with anencephaly.
  • 28.  Inhibin is secreted by the placenta and the corpus luteum.  Inhibin –A is associated with an increased risk of trisomy 21,  A high inhibin –A may be associated with a risk for preterm delivery.
  • 29. Low levels of PAPP-A as measured in maternal serum during the first trimester may be associated with fetal chromosomal anomalies including trisomies 13, 18, and 21 Low PAPP-A levels in the first trimester may predict an adverse pregnancy outcome, including a small for gestational age (SGA) baby or stillbirth. A high PAPP-A level may predict a large for gestational age (LGA) baby.
  • 30.  Combining the maternal serum assays may aid in increasing the sensitivity and specificity of detection for fetal abnormalities.  The classic test is the triple screen for alpha-fetoprotein (MSAFP), beta-HCG, and estriol (uE3). The "quadruple screen" adds inhibin-A.
  • 32.  It is useful in detecting gross fetal parts.  The pattern of gross abnormalities can often suggest a possible chromosomal abnormality or a syndrome.  Consultations are obtained with clinical geneticists to review the findings  Examination of the placenta is very important, because the reason for the fetal loss may be a placental problem
  • 33.  Microscopic examination of the placenta is important Microscopy can aid in determination of gestational age (lung, kidney maturity), presence of infection, presence of neoplasia, or presence of "dysplasia" (abnormal organogenesis).
  • 34.  Radiographic views are essential for analysis of the fetal skeleton.  Radiographs are useful for comparison with prenatal ultrasound, and help define anomalies when autopsy consent is limited  To determine sites to be examined microscopically.
  • 35.  Skeletal anomalies (dwarfism, dysplasia, etc.)  Neural tube defects (anencephaly, spina bifida, etc.)  Osteogenesis imperfecta  Soft tissue changes (hydrops, hygroma, etc.)  Teratomas or other neoplasms  Growth retardation  Orientation and audit of fetal parts  Assessment of catheter or therapeutic device placement
  • 36.  Culture can aid in diagnosis or confirmation of congenital infections:-  T - toxoplasmosis  O - other, such as Listeria monocytogenes, group B streptococcus, syphilis  R - rubella  C - cytomegalovirus  H - herpes simplex or human immunodeficiency virus (HIV)
  • 37.  Tissues must be obtained as fresh as possible for culture and without contamination.  A useful procedure is to wash the tissue samples in sterile saline prior to placing them into cell culture media.  Tissues with the best culture for growth are those with the least maceration: placenta, lung, and diaphragm.  Obtaining tissue from more than one site can increase the yield by avoiding contamination or by detection of mosaicism.
  • 39.  Patient need to sufficiently informed about the implication of genetic screening before they can provide informed consent.  The public view genetic with a sense of inevitability. However, a genetic condition alone may modify risks from environmental or life style factor.  The voluntary nature of the screening process must be emphasized.
  • 40.  To reduce potential psychological distress, counseling should be available to provide information about genetic risk and explain choices regarding genetic testing and further management.  Support is needed for individuals who need to consider issue such as stigma disclosure to family members and confidentiality.
  • 41.  Couple known to carry a recessive or dominance single gene defect or sex linked condition need counseling about their reproductive option. This may include prenatal diagnosis and possible pregnancy termination in the case of an affected fetus and pre-implantation genetic diagnosis.
  • 42.  The public’s understanding of genetic may be limited and can lead to sigma.  Misunderstanding of the genetic risk of developing disease can increase stigmatization. This may be around life expectancy, lifestyle choices, or decision about having children.  Identification of a genetic condition before birth raises issue of whether the parents wish to terminate the pregnancy. Some commentators have argues that the ability to only select perfect babies is a form of eugenesis.
  • 43.  Confidentiality  Like other medical information, result from genetic testing are considered confidential, under normal practice, the doctor patient relationship protect against disclosure of genetic information.  However there is less clarity where relative wish to know the result of a family member’s genetic test, as it may have direct relevance for them.
  • 44.  Another particular dilemma is the case of a pregnant woman wanting to know the result of a test taken by the baby’s father.  The storage of genetic screening data and registries of patients creates particular concern, given that the results may impact negatively on family members.
  • 45.  Doctors face a dilemma when reporting the results of genetic screening. Standard medical practice is based on the principles that doctor’s should focus on their patient and that medical information should remain confidential.  It is unclear if doctors are ethically permitted to inform relatives in cases when the result of genetic test indicates real risk to their health.
  • 46.  Doctors may also be faced with a decision about whether to persuade patient about the need to disclose their test result to relatives.  Although most professional bodies that disclosure should not be against the right of relatives have won priorities.
  • 47.  The primary concerns among the public is the use of genetic information to delay access to health insurance or medical treatment.  Conversely health insurance claim right to access such data where it exist to avoid the moral hazards of patient with known condition taking out an insurance policy without disclosing this information.
  • 50.  Dutta D. C. “ textbook of obstetrics” 6th edition, new central book agency (p) limited, 2009.  Gangane S. D. “human genetics” 3rd edition, Elsevier publishers, 2010.  Mandal Sanjay “ fundamentals of human genetics” 2nd edition, New Central B Book agency, Page no. 209-212.  Perry, Lsowdermilk, “Maternity and women’s health care” 8th edition, mosby an affiliated by Elsevier page no. 67-69.  Sharma, Kumar Suresh, “human genetics in nursing, 2nd edition, Jaypee Publishers, 2011  Internet-www. wikepedia.com www.sparknotes.com www.slideshare.com www.pubmed.com www.nsgc.org www.geneticalliance.org  Dictionary – Oxford essential dictionary. For learners of English, oxford university press.